OTLK Outlook Therapeutics
- 7.561
- -0.169-2.18%
Outlook Therapeutics News
Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment
Outlook Therapeutics to Present at the Retina World Congress 2024
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment
Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevaciz
Outlook Therapeutics Files to Sell 2.78M Shares of Common Stock for Holders
Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
Press Release: Outlook Therapeutics(R) Announces Closing of Private Placement of $5.0 Million
Outlook Therapeutics(R) Announces Closing of Private Placement of $5.0 Million ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company
Outlook Therapeutics Files Prospectus Supplement Related To Offer, Sale Of Up To $93.7M Of Common Stock That May Be Sold Under Sales Agreement
Outlook Therapeutics Files Prospectus Supplement Related To Offer, Sale Of Up To $93.7M Of Common Stock That May Be Sold Under Sales Agreement
Insiders Are Piling Into These 10 Healthcare Stocks in 2024
Insiders Buying Outlook Therapeutics And 2 Other Stocks
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the st
Outlook Therapeutics(OTLK.US) Director Buys US$22,241.83 in Common Stock
$Outlook Therapeutics(OTLK.US)$ Director Haddadin Yezan Munther purchased 1,881.71 shares of Common Stock on Mar 28, 2024 at an average price of $11.82 for a total value of $22,241.83.Source: Announce
Outlook Therapeutics Files for $300M Mixed Securities Shelf
Tang Capital Partners Discloses 9.99% Passive Stake In Outlook Therapeutics
Tang Capital Partners Discloses 9.99% Passive Stake In Outlook Therapeutics
Outlook Therapeutics Shares Rise After BTIG Upgrade
Outlook Therapeutics (OTLK) shares rose 9% in recent trading Wednesday after BTIG upgraded its rating on the stock to buy from neutral. Trading volume topped 1.31 million shares versus the daily avera
Outlook Therapeutics Raised to Buy From Neutral by BTIG
Outlook Therapeutics Raised to Buy From Neutral by BTIG
BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $50 price target.
Buy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Target
Outlook Therapeutics Grants Stock Options to Top Executives
Outlook Therapeutics Reports Secondary Share Offering
Outlook Therapeutics (OTLK) reported late Monday its stockholders may sell up to about 21.43 million shares, including some 12.86 million shares issuable upon the exercise of warrants, with the filing
Outlook Therapeutics Files to Sell 21.43M Common Shares for Holders
Outlook Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Outlook Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Analysis
Price Target
No Data
